Warning of an Increased Risk of Vertebral Fracture After Stopping Denosumab

Overview

Journal CMAJ

Date 2018 Apr 25

PMID 29685907

Citations 8

Authors

Christopher Symonds

Gregory Kline

Affiliations

Soon will be listed here.

Citing Articles

Comparison of Hounsfield Units and Vertebral Bone Quality Score for the Prediction of Time to Pathologic Fracture in Mobile Spine Metastases Treated With Radiotherapy.

Chu P, Yen H, Huang P, Hu M Global Spine J. 2025; :21925682251325173.

PMID: 40036047 PMC: 11881092. DOI: 10.1177/21925682251325173.

Multiple Spontaneous Vertebral Fractures in a Younger Post-menopausal Woman Upon Stopping Denosumab Therapy.

Yang Hu X, Leslie W, Kline G JCEM Case Rep. 2023; 1(3):luad042.

PMID: 37908566 PMC: 10580464. DOI: 10.1210/jcemcr/luad042.

First Ecuadorian statement consensus for the evaluation and treatment of osteoporosis.

Rios C, Maldonado G, Vargas S, Gonzalez J, Vera C, Zuniga A Arch Osteoporos. 2023; 18(1):81.

PMID: 37316765 DOI: 10.1007/s11657-023-01263-5.

Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools.

Gates M, Pillay J, Nuspl M, Wingert A, Vandermeer B, Hartling L Syst Rev. 2023; 12(1):51.

PMID: 36945065 PMC: 10029308. DOI: 10.1186/s13643-023-02181-w.

Real-World Safety and Effectiveness of Denosumab in Patients with Osteoporosis: A Prospective, Observational Study in South Korea.

Rhee Y, Chang D, Ha J, Kim S, Lee Y, Jo E Endocrinol Metab (Seoul). 2022; 37(3):497-505.

PMID: 35654577 PMC: 9262695. DOI: 10.3803/EnM.2022.1427.

References

Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen E, Guanabens N . Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. Bone. 2017; 105:11-17. DOI: 10.1016/j.bone.2017.08.003. View

Modi A, Sajjan S, Insinga R, Weaver J, Lewiecki E, Harris S . Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years. Osteoporos Int. 2017; 28(4):1355-1363. DOI: 10.1007/s00198-016-3886-y. View

Burden A, Paterson J, Solomon D, Mamdani M, Juurlink D, Cadarette S . Bisphosphonate prescribing, persistence and cumulative exposure in Ontario, Canada. Osteoporos Int. 2011; 23(3):1075-82. PMC: 3277689. DOI: 10.1007/s00198-011-1645-7. View

Burden A, Tadrous M, Calzavara A, Cadarette S . Uptake and characteristics of zoledronic acid and denosumab patients and physicians in Ontario, Canada: impact of drug formulary access. Osteoporos Int. 2015; 26(5):1525-33. DOI: 10.1007/s00198-014-3023-8. View

Bone H, Wagman R, Brandi M, Brown J, Chapurlat R, Cummings S . 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017; 5(7):513-523. DOI: 10.1016/S2213-8587(17)30138-9. View

Bone H, Bolognese M, Yuen C, Kendler D, Miller P, Yang Y . Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab. 2011; 96(4):972-80. DOI: 10.1210/jc.2010-1502. View

Anastasilakis A, Polyzos S, Makras P, Aubry-Rozier B, Kaouri S, Lamy O . Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases. J Bone Miner Res. 2017; 32(6):1291-1296. DOI: 10.1002/jbmr.3110. View

Leder B . An Essential Warning. J Bone Miner Res. 2017; 33(2):188-189. DOI: 10.1002/jbmr.3359. View

Lenart B, Lorich D, Lane J . Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med. 2008; 358(12):1304-6. DOI: 10.1056/NEJMc0707493. View

10.

Crandall C, Newberry S, Diamant A, Lim Y, Gellad W, Booth M . Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review. Ann Intern Med. 2014; 161(10):711-23. DOI: 10.7326/M14-0317. View

11.

Cummings S, Ferrari S, Eastell R, Gilchrist N, Jensen J, McClung M . Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension. J Bone Miner Res. 2017; 33(2):190-198. DOI: 10.1002/jbmr.3337. View

12.

Cummings S, San Martin J, McClung M, Siris E, Eastell R, Reid I . Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009; 361(8):756-65. DOI: 10.1056/NEJMoa0809493. View